<p>Live Oak Private Wealth LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股减少了 92.5%。该公司在季度内出售了 216,868 股后，持有 17,627 股生物制药公司的股票。Live Oak Private Wealth LLC 在辉瑞的持股在最近的报告期末价值为 449,000 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
</ul>
<p>其他几家对冲基金和机构投资者也买卖了 PFE 的股票。Capital Advisory Group Advisory Services LLC 在第二季度将其在辉瑞的持股增加了 2.9%。Capital Advisory Group Advisory Services LLC 现在持有 13,542 股生物制药公司的股票，价值 328,000 美元，此前在该期间内又购买了 388 股。Citizens National Bank Trust Department 在第二季度将其在辉瑞的持股增加了 0.9%。Citizens National Bank Trust Department 现在持有 46,103 股生物制药公司的股票，价值 1,118,000 美元，此前在该期间内又购买了 395 股。Peak Asset Management LLC 在第二季度将其在辉瑞的持股增加了 1.4%。Peak Asset Management LLC 现在持有 28,768 股生物制药公司的股票，价值 697,000 美元，此前在上个季度又购买了 402 股。Able Wealth Management LLC 在第二季度将其在辉瑞的持股增加了 2.0%。Able Wealth Management LLC 现在持有 21,128 股生物制药公司的股票，价值 512,000 美元，此前在该期间内又购买了 413 股。最后，Boltwood Capital Management 在第三季度将其在辉瑞的持股增加了 0.7%。Boltwood Capital Management 现在持有 58,274 股生物制药公司的股票，价值 1,485,000 美元，此前在上个季度又购买了 420 股。机构投资者和对冲基金持有该公司 68.36% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>几位研究分析师最近对该股票发布了报告。Scotiabank 在 11 月 13 日的研究报告中开始覆盖辉瑞的股票。他们对该股票设定了 “行业表现优于大盘” 的评级和 30.00 美元的目标价。美国银行在 12 月 15 日的报告中将辉瑞的目标价从 29.00 美元下调至 28.00 美元，并对该公司设定了 “中性” 评级。Wolfe Research 在 12 月 17 日的研究报告中对辉瑞设定了 24.00 美元的目标价，并给予该股票 “表现不佳” 的评级。BMO Capital Markets 在 12 月 10 日的研究报告中重申了辉瑞的 “表现优于大盘” 评级。最后，Wall Street Zen 在 9 月 28 日的研究报告中将辉瑞的评级从 “买入” 下调至 “持有”。两位股票研究分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，十二位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，辉瑞的平均评级为 “持有”，平均目标价为 28.06 美元。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p><strong>查看我们关于 PFE 的最新研究报告</strong></p>
<h2>辉瑞价格表现</h2>
<p>辉瑞（NYSE PFE）周一开盘价为 25.10 美元。该公司的市值为 1426.8 亿美元，市盈率为 14.59，贝塔值为 0.46。该公司的速动比率为 0.97，流动比率为 1.28，债务与股本比率为 0.62。该股票的 50 日移动平均价格为 25.16 美元，200 日移动平均价格为 24.89 美元。辉瑞公司的 12 个月低点为 20.92 美元，12 个月高点为 27.69 美元。</p>
<ul>
<li>HIMS 的股价波动不定。投资者应该入场吗？</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 11 月 4 日发布了季度财报。这家生物制药公司报告季度每股收益为 0.87 美元，超出分析师一致预期的 0.79 美元，超出幅度为 0.08 美元。该业务的季度收入为 166.5 亿美元，而分析师预期为 169.4 亿美元。辉瑞的股本回报率为 20.17%，净利润率为 15.65%。辉瑞已将其 2025 财年的指导目标设定为每股收益 3.000-3.150 美元。平均而言，股票分析师预计辉瑞公司本年度每股收益为 2.95 美元。</p>
<h2>辉瑞分红公告</h2>
<p>该公司最近还宣布了一项季度分红，将于 3 月 6 日（星期五）支付。1 月 23 日（星期五）的登记投资者将获得 0.43 美元的分红。这相当于年化 1.72 美元的分红和 6.9% 的分红收益率。该分红的除息日为 1 月 23 日（星期五）。辉瑞的派息比率为 100.00%。</p>
<h2>辉瑞简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司 NYSE: PFE 是一家总部位于纽约市的跨国生物制药公司。该公司成立于 1849 年，由查尔斯·辉瑞和查尔斯·厄哈特创立，专注于研究、开发、生产和商业化广泛的人类健康药物和疫苗。其活动涵盖发现研究、临床开发、监管事务、生产和多个治疗领域的全球商业分销。</p>
<p>辉瑞的产品组合和管道涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及相当可观的疫苗业务。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比辉瑞更好</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>100 万美元在退休中能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><strong>想看看其他对冲基金持有的 PFE 吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>Live Oak Private Wealth LLC 在第三季度大幅减少了对辉瑞公司的持股，减持幅度达到 92.5%，目前持有 17,627 股，市值为 449,000 美元。其他机构投资者也对辉瑞进行了仓位调整。分析师对该股票的评级褒贬不一，平均目标价为 28.06 美元。辉瑞的股票开盘价为 25.10 美元，市值为 1,426.8 亿美元。该公司报告上个季度每股收益为 0.87 美元，超出预期，并宣布将于 3 月 6 日支付每股 0.43 美元的季度股息</p>

<p>Live Oak Private Wealth LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 92.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 17,627 shares of the biopharmaceutical company's stock after selling 216,868 shares during the quarter. Live Oak Private Wealth LLC's holdings in Pfizer were worth $449,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Live Oak Private Wealth LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股减少了 92.5%。该公司在季度内出售了 216,868 股后，持有 17,627 股生物制药公司的股票。Live Oak Private Wealth LLC 在辉瑞的持股在最近的报告期末价值为 449,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Capital Advisory Group Advisory Services LLC lifted its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after purchasing an additional 388 shares during the period. Citizens National Bank Trust Department lifted its stake in Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after buying an additional 395 shares during the period. Peak Asset Management LLC boosted its holdings in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after buying an additional 402 shares in the last quarter. Able Wealth Management LLC grew its position in shares of Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock worth $512,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management increased its stake in shares of Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company's stock valued at $1,485,000 after acquiring an additional 420 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者也买卖了 PFE 的股票。Capital Advisory Group Advisory Services LLC 在第二季度将其在辉瑞的持股增加了 2.9%。Capital Advisory Group Advisory Services LLC 现在持有 13,542 股生物制药公司的股票，价值 328,000 美元，此前在该期间内又购买了 388 股。Citizens National Bank Trust Department 在第二季度将其在辉瑞的持股增加了 0.9%。Citizens National Bank Trust Department 现在持有 46,103 股生物制药公司的股票，价值 1,118,000 美元，此前在该期间内又购买了 395 股。Peak Asset Management LLC 在第二季度将其在辉瑞的持股增加了 1.4%。Peak Asset Management LLC 现在持有 28,768 股生物制药公司的股票，价值 697,000 美元，此前在上个季度又购买了 402 股。Able Wealth Management LLC 在第二季度将其在辉瑞的持股增加了 2.0%。Able Wealth Management LLC 现在持有 21,128 股生物制药公司的股票，价值 512,000 美元，此前在该期间内又购买了 413 股。最后，Boltwood Capital Management 在第三季度将其在辉瑞的持股增加了 0.7%。Boltwood Capital Management 现在持有 58,274 股生物制药公司的股票，价值 1,485,000 美元，此前在上个季度又购买了 420 股。机构投资者和对冲基金持有该公司 68.36% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research analysts recently issued reports on the stock. Scotiabank assumed coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $30.00 target price on the stock. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a &#34;neutral&#34; rating for the company in a report on Monday, December 15th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an &#34;underperform&#34; rating in a research report on Wednesday, December 17th. BMO Capital Markets reaffirmed an &#34;outperform&#34; rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Wall Street Zen downgraded Pfizer from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pfizer has an average rating of &#34;Hold&#34; and an average target price of $28.06.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发布了报告。Scotiabank 在 11 月 13 日的研究报告中开始覆盖辉瑞的股票。他们对该股票设定了 “行业表现优于大盘” 的评级和 30.00 美元的目标价。美国银行在 12 月 15 日的报告中将辉瑞的目标价从 29.00 美元下调至 28.00 美元，并对该公司设定了 “中性” 评级。Wolfe Research 在 12 月 17 日的研究报告中对辉瑞设定了 24.00 美元的目标价，并给予该股票 “表现不佳” 的评级。BMO Capital Markets 在 12 月 10 日的研究报告中重申了辉瑞的 “表现优于大盘” 评级。最后，Wall Street Zen 在 9 月 28 日的研究报告中将辉瑞的评级从 “买入” 下调至 “持有”。两位股票研究分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，十二位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，辉瑞的平均评级为 “持有”，平均目标价为 28.06 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on PFE</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PFE 的最新研究报告</strong></p>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>辉瑞价格表现</h2>
</div><p>Shares of NYSE PFE opened at $25.10 on Monday. The company has a market capitalization of $142.68 billion, a PE ratio of 14.59 and a beta of 0.46. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The stock's 50 day moving average price is $25.16 and its 200-day moving average price is $24.89. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.</p>
<div class="lb-trans"><p>辉瑞（NYSE PFE）周一开盘价为 25.10 美元。该公司的市值为 1426.8 亿美元，市盈率为 14.59，贝塔值为 0.46。该公司的速动比率为 0.97，流动比率为 1.28，债务与股本比率为 0.62。该股票的 50 日移动平均价格为 25.16 美元，200 日移动平均价格为 24.89 美元。辉瑞公司的 12 个月低点为 20.92 美元，12 个月高点为 27.69 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股价波动不定。投资者应该入场吗？</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 11 月 4 日发布了季度财报。这家生物制药公司报告季度每股收益为 0.87 美元，超出分析师一致预期的 0.79 美元，超出幅度为 0.08 美元。该业务的季度收入为 166.5 亿美元，而分析师预期为 169.4 亿美元。辉瑞的股本回报率为 20.17%，净利润率为 15.65%。辉瑞已将其 2025 财年的指导目标设定为每股收益 3.000-3.150 美元。平均而言，股票分析师预计辉瑞公司本年度每股收益为 2.95 美元。</p>
</div><h2>Pfizer Dividend Announcement</h2>
<div class="lb-trans"><h2>辉瑞分红公告</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer's payout ratio is 100.00%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 3 月 6 日（星期五）支付。1 月 23 日（星期五）的登记投资者将获得 0.43 美元的分红。这相当于年化 1.72 美元的分红和 6.9% 的分红收益率。该分红的除息日为 1 月 23 日（星期五）。辉瑞的派息比率为 100.00%。</p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>辉瑞简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>辉瑞公司 NYSE: PFE 是一家总部位于纽约市的跨国生物制药公司。该公司成立于 1849 年，由查尔斯·辉瑞和查尔斯·厄哈特创立，专注于研究、开发、生产和商业化广泛的人类健康药物和疫苗。其活动涵盖发现研究、临床开发、监管事务、生产和多个治疗领域的全球商业分销。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>辉瑞的产品组合和管道涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及相当可观的疫苗业务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比辉瑞更好</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>100 万美元在退休中能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 PFE 吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Live Oak Private Wealth LLC Has $449,000 Stake in Pfizer Inc. $PFE

- Live Oak Private Wealth LLC 在第三季度将对辉瑞公司的持股减少 92.5%。  
- 其持仓在近期报告结束时为 17,627 股，价值约 449,000 美元。  
- 机构投资者目前持有辉瑞股票的 68.36%。

Live Oak Private Wealth LLC 持有辉瑞公司价值 44.9 万美元的股份